SGLT2 inhibitor improves the prognosis of patients with coronary heart disease and prevents in-stent restenosis
Coronary heart disease is a narrowing or obstruction of the vascular cavity caused by atherosclerosis of the coronary arteries, which leads to myocardial ischemia and hypoxia. At present, percutaneous coronary intervention (PCI) is an effective treatment for coronary atherosclerotic heart disease. R...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-01-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2023.1280547/full |
| _version_ | 1827383932099756032 |
|---|---|
| author | Qing Zhang Zhiwen Deng Tudi Li Kaitong Chen Zhihuan Zeng |
| author_facet | Qing Zhang Zhiwen Deng Tudi Li Kaitong Chen Zhihuan Zeng |
| author_sort | Qing Zhang |
| collection | DOAJ |
| description | Coronary heart disease is a narrowing or obstruction of the vascular cavity caused by atherosclerosis of the coronary arteries, which leads to myocardial ischemia and hypoxia. At present, percutaneous coronary intervention (PCI) is an effective treatment for coronary atherosclerotic heart disease. Restenosis is the main limiting factor of the long-term success of PCI, and it is also a difficult problem in the field of intervention. Sodium-glucose cotransporter 2 (SGLT2) inhibitor is a new oral glucose-lowering agent used in the treatment of diabetes in recent years. Recent studies have shown that SGLT2 inhibitors can effectively improve the prognosis of patients after PCI and reduce the occurrence of restenosis. This review provides an overview of the clinical studies and mechanisms of SGLT2 inhibitors in the prevention of restenosis, providing a new option for improving the clinical prognosis of patients after PCI. |
| first_indexed | 2024-03-08T14:48:41Z |
| format | Article |
| id | doaj.art-1b64e9f8c92247cd9823fe270a47501e |
| institution | Directory Open Access Journal |
| issn | 2297-055X |
| language | English |
| last_indexed | 2024-03-08T14:48:41Z |
| publishDate | 2024-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj.art-1b64e9f8c92247cd9823fe270a47501e2024-01-11T04:50:27ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2024-01-011010.3389/fcvm.2023.12805471280547SGLT2 inhibitor improves the prognosis of patients with coronary heart disease and prevents in-stent restenosisQing ZhangZhiwen DengTudi LiKaitong ChenZhihuan ZengCoronary heart disease is a narrowing or obstruction of the vascular cavity caused by atherosclerosis of the coronary arteries, which leads to myocardial ischemia and hypoxia. At present, percutaneous coronary intervention (PCI) is an effective treatment for coronary atherosclerotic heart disease. Restenosis is the main limiting factor of the long-term success of PCI, and it is also a difficult problem in the field of intervention. Sodium-glucose cotransporter 2 (SGLT2) inhibitor is a new oral glucose-lowering agent used in the treatment of diabetes in recent years. Recent studies have shown that SGLT2 inhibitors can effectively improve the prognosis of patients after PCI and reduce the occurrence of restenosis. This review provides an overview of the clinical studies and mechanisms of SGLT2 inhibitors in the prevention of restenosis, providing a new option for improving the clinical prognosis of patients after PCI.https://www.frontiersin.org/articles/10.3389/fcvm.2023.1280547/fullSGLT2 inhibitorrestenosiscoronary heart diseaseAMI—acute myocardial infarctionASCVD-atherosclerotic cardiovascular disease |
| spellingShingle | Qing Zhang Zhiwen Deng Tudi Li Kaitong Chen Zhihuan Zeng SGLT2 inhibitor improves the prognosis of patients with coronary heart disease and prevents in-stent restenosis Frontiers in Cardiovascular Medicine SGLT2 inhibitor restenosis coronary heart disease AMI—acute myocardial infarction ASCVD-atherosclerotic cardiovascular disease |
| title | SGLT2 inhibitor improves the prognosis of patients with coronary heart disease and prevents in-stent restenosis |
| title_full | SGLT2 inhibitor improves the prognosis of patients with coronary heart disease and prevents in-stent restenosis |
| title_fullStr | SGLT2 inhibitor improves the prognosis of patients with coronary heart disease and prevents in-stent restenosis |
| title_full_unstemmed | SGLT2 inhibitor improves the prognosis of patients with coronary heart disease and prevents in-stent restenosis |
| title_short | SGLT2 inhibitor improves the prognosis of patients with coronary heart disease and prevents in-stent restenosis |
| title_sort | sglt2 inhibitor improves the prognosis of patients with coronary heart disease and prevents in stent restenosis |
| topic | SGLT2 inhibitor restenosis coronary heart disease AMI—acute myocardial infarction ASCVD-atherosclerotic cardiovascular disease |
| url | https://www.frontiersin.org/articles/10.3389/fcvm.2023.1280547/full |
| work_keys_str_mv | AT qingzhang sglt2inhibitorimprovestheprognosisofpatientswithcoronaryheartdiseaseandpreventsinstentrestenosis AT zhiwendeng sglt2inhibitorimprovestheprognosisofpatientswithcoronaryheartdiseaseandpreventsinstentrestenosis AT tudili sglt2inhibitorimprovestheprognosisofpatientswithcoronaryheartdiseaseandpreventsinstentrestenosis AT kaitongchen sglt2inhibitorimprovestheprognosisofpatientswithcoronaryheartdiseaseandpreventsinstentrestenosis AT zhihuanzeng sglt2inhibitorimprovestheprognosisofpatientswithcoronaryheartdiseaseandpreventsinstentrestenosis |